PHILOGEN SPA (PHIL.MI) Fundamental Analysis & Valuation

BIT:PHILIT0005373789

Current stock price

20.85 EUR
+0.05 (+0.24%)
Last:

This PHIL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. PHIL.MI Profitability Analysis

1.1 Basic Checks

  • PHIL had positive earnings in the past year.
  • In the past year PHIL had a positive cash flow from operations.
  • In the past 5 years PHIL reported 4 times negative net income.
  • In the past 5 years PHIL reported 4 times negative operating cash flow.
PHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFPHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 28.81%, PHIL belongs to the top of the industry, outperforming 97.22% of the companies in the same industry.
  • PHIL has a Return On Equity of 36.49%. This is amongst the best in the industry. PHIL outperforms 97.22% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 21.08%, PHIL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROIC 21.08%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHIL.MI Yearly ROA, ROE, ROICPHIL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

  • PHIL has a Profit Margin of 58.33%. This is amongst the best in the industry. PHIL outperforms 95.83% of its industry peers.
  • In the last couple of years the Profit Margin of PHIL has grown nicely.
  • PHIL has a better Operating Margin (49.47%) than 97.22% of its industry peers.
  • The Gross Margin of PHIL (74.04%) is better than 69.44% of its industry peers.
  • In the last couple of years the Gross Margin of PHIL has grown nicely.
Industry RankSector Rank
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
PHIL.MI Yearly Profit, Operating, Gross MarginsPHIL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

9

2. PHIL.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHIL is creating value.
  • The number of shares outstanding for PHIL remains at a similar level compared to 1 year ago.
  • PHIL has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PHIL has an improved debt to assets ratio.
PHIL.MI Yearly Shares OutstandingPHIL.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHIL.MI Yearly Total Debt VS Total AssetsPHIL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 13.20 indicates that PHIL is not in any danger for bankruptcy at the moment.
  • PHIL has a better Altman-Z score (13.20) than 90.28% of its industry peers.
  • PHIL has a debt to FCF ratio of 0.31. This is a very positive value and a sign of high solvency as it would only need 0.31 years to pay back of all of its debts.
  • PHIL has a better Debt to FCF ratio (0.31) than 91.67% of its industry peers.
  • PHIL has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.08, PHIL is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Altman-Z 13.2
ROIC/WACC2.65
WACC7.94%
PHIL.MI Yearly LT Debt VS Equity VS FCFPHIL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • PHIL has a Current Ratio of 5.73. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
  • PHIL has a better Current ratio (5.73) than 83.33% of its industry peers.
  • A Quick Ratio of 5.52 indicates that PHIL has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 5.52, PHIL belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 5.52
PHIL.MI Yearly Current Assets VS Current LiabilitesPHIL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

8

3. PHIL.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 255.77% over the past year.
  • Measured over the past years, PHIL shows a very strong growth in Earnings Per Share. The EPS has been growing by 100.72% on average per year.
  • PHIL shows a strong growth in Revenue. In the last year, the Revenue has grown by 3346.54%.
  • The Revenue has been growing by 42.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%

3.2 Future

  • Based on estimates for the next years, PHIL will show a decrease in Earnings Per Share. The EPS will decrease by -3.40% on average per year.
  • Based on estimates for the next years, PHIL will show a very strong growth in Revenue. The Revenue will grow by 22.55% on average per year.
EPS Next Y14.73%
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
EPS Next 5Y-3.4%
Revenue Next Year112.03%
Revenue Next 2Y-33.5%
Revenue Next 3Y-32.44%
Revenue Next 5Y22.55%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PHIL.MI Yearly Revenue VS EstimatesPHIL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PHIL.MI Yearly EPS VS EstimatesPHIL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

6

4. PHIL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • PHIL is valuated rather expensively with a Price/Earnings ratio of 18.29.
  • Compared to the rest of the industry, the Price/Earnings ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 83.33% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.91. PHIL is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 16.69, which indicates a correct valuation of PHIL.
  • Based on the Price/Forward Earnings ratio, PHIL is valued cheaper than 88.89% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.99. PHIL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 18.29
Fwd PE 16.69
PHIL.MI Price Earnings VS Forward Price EarningsPHIL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 87.50% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, PHIL is valued cheaper than 94.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.56
EV/EBITDA 10.02
PHIL.MI Per share dataPHIL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • PHIL has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as PHIL's earnings are expected to decrease with -63.96% in the coming years.
PEG (NY)1.24
PEG (5Y)0.18
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%

4

5. PHIL.MI Dividend Analysis

5.1 Amount

  • PHIL has a Yearly Dividend Yield of 3.40%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.81, PHIL pays a better dividend. On top of this PHIL pays more dividend than 94.44% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, PHIL pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.4%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
PHIL.MI Yearly Income VS Free CF VS DividendPHIL.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

PHIL.MI Fundamentals: All Metrics, Ratios and Statistics

PHILOGEN SPA

BIT:PHIL (4/29/2026, 1:07:08 PM)

20.85

+0.05 (+0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength40.54
Industry Growth78
Earnings (Last)03-27
Earnings (Next)05-12
Inst Owners9.26%
Inst Owner ChangeN/A
Ins Owners34.46%
Ins Owner ChangeN/A
Market Cap609.65M
Revenue(TTM)78.72M
Net Income(TTM)45.91M
Analysts80
Price Target22.95 (10.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.4%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.46%
PT rev (3m)-13.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 18.29
Fwd PE 16.69
P/S 7.74
P/FCF 16.56
P/OCF 15.42
P/B 4.85
P/tB 4.89
EV/EBITDA 10.02
EPS(TTM)1.14
EY5.47%
EPS(NY)1.25
Fwd EY5.99%
FCF(TTM)1.26
FCFY6.04%
OCF(TTM)1.35
OCFY6.49%
SpS2.69
BVpS4.3
TBVpS4.26
PEG (NY)1.24
PEG (5Y)0.18
Graham Number10.5054 (-49.61%)
Profitability
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROCE 28.1%
ROIC 21.08%
ROICexc 75.73%
ROICexgc 78.23%
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
FCFM 46.77%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Debt/EBITDA 0.24
Cap/Depr 67.4%
Cap/Sales 3.47%
Interest Coverage 78.84
Cash Conversion 91.98%
Profit Quality 80.19%
Current Ratio 5.73
Quick Ratio 5.52
Altman-Z 13.2
F-Score8
WACC7.94%
ROIC/WACC2.65
Cap/Depr(3y)124.83%
Cap/Depr(5y)196.93%
Cap/Sales(3y)15.46%
Cap/Sales(5y)79.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
EPS Next Y14.73%
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
EPS Next 5Y-3.4%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%
Revenue Next Year112.03%
Revenue Next 2Y-33.5%
Revenue Next 3Y-32.44%
Revenue Next 5Y22.55%
EBIT growth 1Y218.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.81%
EBIT Next 3Y-71.96%
EBIT Next 5YN/A
FCF growth 1Y1324.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6769.31%
OCF growth 3YN/A
OCF growth 5Y135.99%

PHILOGEN SPA / PHIL.MI Fundamental Analysis FAQ

What is the fundamental rating for PHIL stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI.


What is the valuation status for PHIL stock?

ChartMill assigns a valuation rating of 6 / 10 to PHILOGEN SPA (PHIL.MI). This can be considered as Fairly Valued.


What is the profitability of PHIL stock?

PHILOGEN SPA (PHIL.MI) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for PHIL stock?

The Price/Earnings (PE) ratio for PHILOGEN SPA (PHIL.MI) is 18.29 and the Price/Book (PB) ratio is 4.85.


What is the earnings growth outlook for PHILOGEN SPA?

The Earnings per Share (EPS) of PHILOGEN SPA (PHIL.MI) is expected to grow by 14.73% in the next year.